Indications for use
Octagam®5% is indicated for
Replacement therapy in adults, children and adolescents (0-18 years) in:
Primary immunodeficiency syndromes (PID) with impaired antibody production
Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4g/l.
*PSAF=failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypep-tide antigen vaccines
Immunomodulation in adults, and children and adolescents (0-18 years) in:
Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
Guillain Barré syndrome
Kawasaki disease (in conjunction with acetylsalicylic acid)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Multifocal motor neuropathy (MMN)
Octagam®10% is indicated for
Replacement therapy in adults, and children and adolescents (0-18 years) in:
Primary immunodeficiency syndromes (PID) with impaired antibody production
Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4g/l.
*PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypep-tide antigen vaccines
Immunomodulation in adults, and children and adolescents (0-18 years) in:
Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
Guillain Barré syndrome
Kawasaki disease (in conjunction with acetylsalicylic acid)
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Multifocal motor neuropathy (MMN)
Immunomodulation in adults with:
Active dermatomyositis treated with immunosuppressive drugs including corticosteroids, or with intolerance or contra-indications to those drugs
References
3. octagam®5%. Summary of Product Characteristics. May 2021.
4. octagam®10%. Summary of Product Characteristics. May 2021.
This is an international website for octagam® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website.
